Is MOTS-c FDA approved? the straight answer

Last updated 2026-07-25

is MOTS-c FDA approved for any use?

No. There is no FDA-approved drug called MOTS-c, and none of its proposed uses (metabolic disease, muscle preservation, anti-aging) have gone through an FDA new drug application. You can check this yourself in the Drugs@FDA database, the government's own list of approved drug products, and MOTS-c does not appear in it ^[1]. That matters more than it sounds. "FDA approved" is not a vibe or a marketing claim, it's a specific regulatory status that means a sponsor ran the required trials, submitted the data, and the agency signed off on a specific indication, dose, and manufacturing process. MOTS-c has none of that. What it has is a decent pile of preclinical research, almost all in mice, rats, or cultured cells, showing interesting mitochondrial signaling effects ^[2]. So when someone tells you MOTS-c is "FDA approved" or even "in FDA trials," ask them to name the trial. If they can't, they're guessing or selling something.

is MOTS-c legal to buy or use in the US?

This is the part most sellers gloss over. Legality for peptides like MOTS-c hinges on the FDA's bulk drug substances lists under sections 503A and 503B of the Food, Drug, and Cosmetic Act, and MOTS-c is not on either one. The 503A Bulks List (21 CFR 216.23) covers substances a licensed pharmacy can compound into a patient-specific prescription ^[3]. The 503B Bulks List (21 CFR 216.24) covers what an outsourcing facility can use to make office-stock preparations without an individual prescription ^[4]. FDA maintains a running list of substances nominated for evaluation for compounding use, and that nomination process itself doesn't confer legal status; a substance can sit on the "nominated" list for years without ever making the actual Bulks List ^[5]. Pharmacy compounding itself is authorized under 21 U.S.C. 353a, but only for substances that meet specific criteria, including appearing on an official bulks list or otherwise qualifying ^[6]. Without that, a compounded MOTS-c product exists in a gray zone. Not FDA-approved, not clearly authorized for compounding, and typically sold under a "research use only" label that legally means it isn't meant for human consumption at all. That RUO labeling is itself a regulatory signal, tied to how FDA defines "intended use" under 21 CFR 201.128, where a product's marketing and labeling determine what it's legally allowed to be sold for ^[7].

what does the actual research on MOTS-c show?

The foundational paper, published in Cell Metabolism in 2015, found that MOTS-c treatment in mice improved insulin sensitivity and prevented diet-induced obesity, and the effect held up in aged mice too ^[2]. That's the paper most of the current interest traces back to, and it's genuinely a rodent study, not a human trial. A 2018 Cell Metabolism paper showed something mechanistically interesting: under metabolic stress, MOTS-c translocates into the cell nucleus and directly regulates gene expression tied to antioxidant response, a function distinct from most peptide hormones, which work from outside the cell ^[8]. A 2019 review in BioEssays frames MOTS-c as a mitochondrial-encoded messenger to the nucleus, part of a broader signaling system that lets mitochondria talk back to the genome ^[9]. Since then the preclinical output has grown fast, and fast is the right word, because it's still almost entirely non-human. A 2023 Frontiers in Endocrinology paper calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation" based on its metabolic and cytoprotective signaling profile ^[10], and a 2023 Metabolites paper reviews evidence that MOTS-c functionally prevents metabolic disorders across several rodent and cell models ^[11]. None of this is a human clinical trial. All of it is worth watching. Those are two different statements and people conflate them constantly.

does MOTS-c help with diabetes or insulin resistance?

In rodent and cell models, yes, repeatedly. Whether that holds in humans is genuinely unknown. A 2022 Pharmacological Research study found MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model ^[12]. A 2025 paper in Experimental & Molecular Medicine reported that MOTS-c prevents pancreatic islet cell senescence, potentially delaying diabetes onset in the model studied ^[13]. A 2023 review in Diabetes & Metabolism Journal ties MOTS-c to diabetes and aging-related disease pathways broadly ^[14], and a 2025 Cardiovascular Drugs and Therapy paper even asks outright whether MOTS-c is a "magical molecule" for diabetic cardiomyopathy, a title that tells you the field's enthusiasm has outpaced its clinical proof ^[15]. There's also a 2025 Scientific Reports paper showing MOTS-c mimicked some effects of exercise in combating diabetic liver fibrosis in a rodent model, working through Keap1-Nrf2-Smad2/3 signaling ^[16]. That's the closest thing to a mechanistic basis for the "exercise mimetic" label, and it's still a rodent liver fibrosis model, not a claim that injecting MOTS-c replaces a workout in a person.

is MOTS-c really an "exercise in a pill"?

That phrase is marketing shorthand, not a study finding, and no cited paper claims MOTS-c replaces exercise in humans. What's actually true: MOTS-c levels change with exercise, and the peptide appears to be part of the mitohormesis response, the process by which mild mitochondrial stress from exercise triggers adaptive signaling. A 2022 review in Diabetes & Metabolism Journal covers this relationship directly, describing MOTS-c's role in exercise-induced mitohormesis ^[17]. A 2021 review in Biochimica et Biophysica Acta looks at mitochondrial-derived peptides and exercise more broadly, again as an observational and mechanistic account, not a substitution claim ^[18]. Separately, a 2021 paper in American Journal of Physiology found MOTS-c reduced myostatin and muscle atrophy signaling in a rodent model ^[19], and a 2024 study in the same journal found MOTS-c attenuated immobilization-induced muscle atrophy by suppressing lipid infiltration ^[20]. Interesting muscle biology. Still not evidence that a healthy person taking MOTS-c gets the cardiovascular, bone, and cognitive benefits of an actual training program. If you want the honest breakdown of what the muscle and mitochondrial data does and doesn't support, our MOTS-c hub page walks through it study by study.

has MOTS-c been tested in human clinical trials?

There's no completed, published human clinical trial establishing MOTS-c's safety or efficacy for any indication that we can point to. The 2023 Frontiers in Endocrinology review characterizes MOTS-c as a candidate "for therapeutic exploitation," language that describes potential, not proof ^[10]. A 2026 Sports Medicine paper reviewing safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is a useful reality check here: it evaluates peptides used off-label or informally in sports medicine, and the framing itself (approved vs. unapproved) signals that MOTS-c sits in the unapproved category alongside a long list of similarly hyped but clinically unproven compounds ^[21]. One finding that should give anyone pause before assuming "more mitochondrial peptide is always good": a 2018 paper in Rejuvenation Research found that certain mitochondrial-derived peptides can exacerbate cellular senescence under some conditions ^[22]. Biology is rarely one-directional. A peptide with plausible anti-aging mechanisms in one context can plausibly do the opposite in another. That's exactly the kind of nuance a human trial is designed to catch, and MOTS-c hasn't had one yet.

what other conditions is MOTS-c being studied for?

A lot, honestly, almost all preclinical. The breadth is part of why MOTS-c gets so much attention, and also part of why none of it should be read as an approved use. Cancer: a 2024 Advanced Science paper found MOTS-c suppressed ovarian cancer progression in a study model by attenuating a specific deubiquitination pathway ^[23]. Lung injury: a 2025 Redox Biology paper found MOTS-c attenuated lung ischemia-reperfusion injury via a MYH9-dependent mechanism ^[24], while a 2023 European Journal of Pharmacology paper found it suppressed ferroptosis and reduced acute lung injury from myocardial ischemia reperfusion ^[25]. Fibrosis: a 2023 Mitochondrion paper flags MOTS-c as a potential anti-pulmonary fibrosis factor ^[26]. Bone and joint: a 2023 Frontiers in Physiology review covers MOTS-c's role in bone metabolism regulation ^[27], and a 2025 Free Radical Biology & Medicine paper found MOTS-c attenuated cartilage degradation in an osteoarthritis model through an Nrf2-dependent mechanism ^[28]. Infection: a 2024 Gut paper found a novel antiviral role for MOTS-c during HBV infection tied to mitochondrial remodeling ^[29]. Even asthma and cell membrane repair have papers: a 2025 International Immunopharmacology study on airway barrier dysfunction ^[30] and a 2024 Theranostics paper on plasma membrane repair via TRIM72 translocation ^[31]. This is a molecule with unusually wide mechanistic reach. Wide reach in cell and animal models is not the same as clinical readiness in any one of these areas.

why do people compound and sell MOTS-c if it isn't approved?

Because the regulatory gray zone is wide enough to drive a business through, and demand from the biohacking and longevity community is real. Sellers typically label MOTS-c "for research use only," which legally means it should not be sold for human use at all, yet the product is frequently marketed with language that strongly implies otherwise. This is where FDA's "intended use" doctrine under 21 CFR 201.128 actually bites: what a product is legally allowed to be depends heavily on how it's labeled and marketed, more than what's printed on the vial ^[7]. A company selling an unapproved peptide with wellness claims plastered around it is inviting exactly the kind of scrutiny that doctrine exists to catch. If you're going to use MOTS-c anyway, and plenty of people in the longevity space are, the meaningful choice isn't whether to accept some risk (any unapproved peptide carries risk you can't fully price), it's how much of that risk you can strip out. That means going through a provider who reviews your health history before anything ships, sourced through a licensed pharmacy partner rather than an anonymous research-chemical storefront. MOTS-c Co works with a provider-reviewed process for exactly this reason: it doesn't compound or manufacture anything, it connects people to that reviewed pathway and a named pharmacy fulfillment partner instead of leaving you to guess at purity and dosing on your own.

what's the mechanism that makes MOTS-c different from other peptides?

MOTS-c is encoded in mitochondrial DNA, specifically within the 12S rRNA gene, which makes it structurally unusual: most peptide hormones come from nuclear genes, not the mitochondrial genome. That origin is baked into its name (Mitochondrial Open Reading Frame of the 12S rRNA type-c). The mechanism that gets researchers most excited is the nuclear translocation finding from the 2018 Cell Metabolism paper: under metabolic stress, MOTS-c moves into the nucleus and directly regulates gene expression, acting as a kind of mitochondria-to-nucleus messenger rather than just a circulating hormone ^[8]. A 2024 iScience paper adds a specific mechanistic detail in skeletal muscle, finding MOTS-c binds and activates the enzyme CK2 directly, modulating muscle function through that pathway ^[32]. This dual-compartment biology (acting locally in mitochondria, in the cytoplasm, and in the nucleus) is genuinely unusual among human-derived peptides and is a big part of why basic scientists keep publishing on it. It's also exactly the kind of complex, multi-pathway mechanism that tends to take a long time, and a lot of failed intermediate compounds, before it turns into an approved drug, if it ever does.

how should I think about MOTS-c dosing if there's no approved protocol?

There isn't an FDA-approved dose, an approved route of administration, or an approved formulation, so anything you see quoted as a "standard protocol" is coming from anecdotal use, compounding pharmacy convention, or extrapolation from animal study dosing, not from a regulatory label. That's a real gap, and it's one reason self-dosing off internet forum numbers is a worse idea than it looks. Animal doses don't translate to human doses in a simple linear way, and none of the cited studies here were designed to establish a safe or effective human dosing range; they were designed to test mechanisms in mice, rats, or cell cultures. If you want a fuller breakdown of how existing protocols are typically structured and where the numbers actually come from, see our MOTS-c dosage guide, our how to take MOTS-c peptide walkthrough, and the MOTS-c dosage calculator for working through the numbers people commonly reference. Injection site and timing questions come up constantly too, and while there's no approved answer to either, our MOTS-c injection sites piece and best time of day to take MOTS-c peptide article cover what's commonly practiced and why, with the same caveat: commonly practiced isn't the same as clinically validated.

what should I actually take away from all this?

MOTS-c is real, mitochondrially encoded, and mechanistically fascinating; it is not an approved drug, it's not on either FDA compounding bulks list, and nobody has published a completed human trial proving it does what the rodent studies suggest. Those three facts can all be true at once, and they are. If a seller tells you MOTS-c fixes diabetes, reverses aging, or is "basically FDA approved because it's natural," that's marketing outrunning the science, full stop. The honest version: this is early-stage, mechanistically rich, preclinically promising research on a peptide your own mitochondria already make small amounts of, and the human clinical evidence hasn't caught up to the animal data yet. That gap is the actual story, not a footnote to it.

Frequently asked questions

Is MOTS-c approved by the FDA?

No. There is no FDA-approved drug product named MOTS-c in the Drugs@FDA database, and it has no approved human indication ^[1]. All available evidence comes from cell and animal studies, not approved clinical trials.

Is MOTS-c legal to buy in the United States?

It occupies a gray zone. MOTS-c isn't on FDA's 503A or 503B bulk drug substances lists ^[3][4], so lawful pharmacy compounding into a prescription drug is questionable, and most vials are sold labeled "research use only," which legally excludes human use.

Has MOTS-c been tested in human clinical trials?

Not that has been published to date. Every cited study here is a rodent, cell-culture, or ex vivo model. A 2023 Frontiers in Endocrinology review describes MOTS-c as promising "for therapeutic exploitation," language for potential, not proof of human efficacy ^[11].

Does MOTS-c really mimic exercise?

It's linked to exercise-induced mitohormesis signaling, and rodent studies show exercise-like metabolic effects, including one 2025 Scientific Reports study on diabetic liver fibrosis ^[17]. "Exercise in a pill" is marketing shorthand; no study shows MOTS-c replicates exercise's full human benefits.

What does MOTS-c actually do in the body?

In cell and animal models, it regulates mitochondrial-to-nuclear signaling under metabolic stress ^[9], improves insulin sensitivity and reduces obesity in mice ^[2], and activates CK2 in skeletal muscle ^[33]. It's produced from a small open reading frame within mitochondrial DNA.

Why isn't MOTS-c on the FDA's compounding bulk drug list?

FDA maintains separate 503A (21 CFR 216.23) and 503B (21 CFR 216.24) bulks lists, and getting on either requires nomination, agency evaluation, and approval ^[3][4]. MOTS-c hasn't cleared that process, so pharmacies compounding it operate outside the clearly authorized substance list.

Can a doctor legally prescribe MOTS-c?

Pharmacy compounding is governed by 21 U.S.C. 353a, which requires the compounded substance to meet specific legal criteria, generally including bulks list status ^[6]. Since MOTS-c isn't on the 503A or 503B lists, a prescription for a compounded version sits in legally uncertain territory.

Does MOTS-c help with diabetes in humans?

In rodent models, yes: a 2015 Cell Metabolism study found it improved insulin resistance and reduced obesity ^[2], and a 2022 Pharmacological Research study found it relieved hyperglycemia in a gestational diabetes model ^[13]. No published human trial confirms this effect.

Is MOTS-c safe?

Safety hasn't been established in humans through completed clinical trials. A 2018 Rejuvenation Research paper found some mitochondrial-derived peptides can exacerbate cellular senescence under certain conditions ^[23], a reminder that preclinical benefit doesn't guarantee safety in every context.

What is MOTS-c derived from?

MOTS-c is encoded within a short open reading frame inside the mitochondrial 12S rRNA gene, making it one of a small class of mitochondrial-derived peptides. A 2019 BioEssays review frames it as a mitochondrial-encoded regulator that signals to the cell nucleus ^[10].

Where can I find MOTS-c studies myself?

PubMed (pubmed.ncbi.nlm.nih.gov) indexes all peer-reviewed MOTS-c research; search "MOTS-c" directly. Also check Drugs@FDA (accessdata.fda.gov/scripts/cder/daf) to confirm approval status yourself rather than trusting a seller's claim ^[1].

Why do so many studies exist if MOTS-c isn't approved?

Because it's a scientifically interesting mechanism (mitochondria signaling directly to the nucleus) worth studying, independent of any near-term drug approval. Dozens of preclinical papers since 2015 explore roles in metabolism, muscle, bone, cancer, lung injury, and infection, but volume of preclinical interest doesn't equal clinical readiness.

Sources

1. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product in the official approved drug database
2. Cell Metabolism, 2015 (PMID 25738459): MOTS-c improved insulin resistance and reduced obesity in mice, including aged mice
3. eCFR, 21 CFR 216.23 (503A Bulks List): MOTS-c is not listed on the 503A bulk drug substances list for pharmacy compounding
4. eCFR, 21 CFR 216.24 (503B Bulks List): MOTS-c is not listed on the 503B bulk drug substances list for outsourcing facility compounding
5. FDA, bulk drug substances nominated for compounding (current list): FDA maintains a nominated substances list distinct from the official Bulks List, and nomination alone does not confer legal compounding status
6. Cornell Law, 21 U.S.C. 353a: Pharmacy compounding is legally governed by specific statutory criteria including substance list status
7. eCFR, 21 CFR 201.128: FDA's intended use doctrine determines a product's legal drug status based on labeling and marketing claims
8. Cell Metabolism, 2018 (PMID 29983246): MOTS-c translocates to the nucleus under metabolic stress to regulate nuclear gene expression
9. BioEssays, 2019 (PMID 31378979): MOTS-c functions as a mitochondrial-encoded regulator that signals to the nucleus
10. Frontiers in Endocrinology, 2023 (PMID 36761202): MOTS-c is described as a promising candidate for therapeutic exploitation based on preclinical signaling data
11. Metabolites, 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders across multiple preclinical models
12. Pharmacological Research, 2022 (PMID 34798268): MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes mellitus model
13. Experimental & Molecular Medicine, 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in a study model
14. Diabetes & Metabolism Journal, 2023 (PMID 36824008): MOTS-c is linked to diabetes and aging-related disease pathways broadly in preclinical review
15. Cardiovascular Drugs and Therapy, 2025 (PMID 40172798): A 2025 review questions whether MOTS-c is a therapeutic option for diabetic cardiomyopathy, reflecting preclinical rather than clinical status
16. Scientific Reports, 2025 (PMID 40425777): MOTS-c mimicked exercise effects to combat diabetic liver fibrosis in a rodent model via Keap1-Nrf2-Smad2/3 signaling
17. Diabetes & Metabolism Journal, 2022 (PMID 35656563): MOTS-c participates in exercise-induced mitohormesis signaling
18. Biochimica et Biophysica Acta, 2021 (PMID 34520826): Mitochondrial-derived peptides including MOTS-c are mechanistically linked to exercise response
19. American Journal of Physiology, 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in a preclinical model
20. American Journal of Physiology, 2024 (PMID 38170165): MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
21. Sports Medicine, 2026 (PMID 41966639): A review of approved and unapproved peptide therapies for athletic performance categorizes compounds like MOTS-c as unapproved
22. Rejuvenation Research, 2018 (PMID 30058454): Some mitochondrial-derived peptides can exacerbate cellular senescence under certain conditions
23. Advanced Science, 2024 (PMID 39321430): MOTS-c suppressed ovarian cancer progression in a study model via USP7-mediated LARS1 deubiquitination pathway
24. Redox Biology, 2025 (PMID 40403491): MOTS-c attenuated lung ischemia-reperfusion injury via a MYH9-dependent nuclear translocation mechanism
25. European Journal of Pharmacology, 2023 (PMID 37290680): MOTS-c suppressed ferroptosis and reduced acute lung injury via PPARgamma signaling in a preclinical model
26. Mitochondrion, 2023 (PMID 37307934): MOTS-c is identified as a potential anti-pulmonary fibrosis factor derived from mitochondria
27. Frontiers in Physiology, 2023 (PMID 37200834): MOTS-c plays a role in bone metabolism regulation in preclinical research
28. Free Radical Biology & Medicine, 2025 (PMID 41043625): MOTS-c attenuated cartilage degradation in an osteoarthritis model via an Nrf2-dependent mechanism
29. Gut, 2024 (PMID 37788894): MOTS-c showed a novel antiviral role during HBV infection tied to mitochondrial remodeling
30. International Immunopharmacology, 2025 (PMID 40472776): MOTS-c attenuated airway barrier dysfunction in an allergic asthma model via the Nrf2 pathway
31. Theranostics, 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation
32. iScience, 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2